Abiopharma

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time

Clinical trial NCT05722444 updates: 1. status: UNKNOWN → COMPLETED 2. completion date: 2024-05-31 → 2024-10-17 3. primary completion date: 2024-04-30 → 2024-04-10

Clinical trial NCT07224529 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-05-01 → 2026-06-01

Clinical trial NCT07370467 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. completion date: 2026-01-30 → 2026-09-30 3. primary completion date: 2026-01-30 → 2026-09-30

Clinical trial NCT06947408 updates: 1. status: RECRUITING → COMPLETED 2. completion date: 2026-04-23 → 2026-05-11 3. primary completion date: 2026-04-23 → 2026-05-11 4. enrollment: 60 → 44 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT06097728 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. primary completion date: 2027-11-19 → 2028-11-16 3. enrollment: 825 → 861 participants 4. enrollment type: ESTIMATED → ACTUAL

Atos Group et Microsoft étendent leur collaboration stratégique pour déployer une IA agentique sécurisée auprès des collaborateurs et des clients du Groupe

Syntec Optics (Nasdaq: OPTX) Secures $4.6M Critical-Care Biomedical Order

Atos Group and Microsoft Expand Strategic Collaboration to Scale Secure Agentic AI Across Atos Group Workforce and Clients

Flag Ship Acquisition Corporation Regains Compliance with Nasdaq Listing Rule 5250(c)(1)